BackEstrella Immunopharma- Warrants (29/09/2028) Overview
Estrella Immunopharma Inc - Warrants (29/09/2028)

Estrella Immunopharma- Warrants (29/09/2028) Return on Equity

Estrella Immunopharma- Warrants (29/09/2028) (ESLAW) has a ROE of 251.43%, above the sector sector average of -4.47%.

Get informed when a big investor buys or sells

+ Follow

ROE

251.43%

Return on Equity

251.43%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Estrella Immunopharma- Warrants (29/09/2028) (ESLAW) FAQ

As of the most recent data, ESLAW shows a ROE of 251.43%. That is above the sector sector average of -4.47%. Scroll down for historical charts and peer comparison views.

The its sector sector average ROE is about -4.47%. Estrella Immunopharma- Warrants (29/09/2028) is at 251.43%, which is higher that average. That is roughly 5727.0% above the sector mean. Use the comparison chart on this page to see how ESLAW stacks up against individual peers as well.

Check the historical chart to see whether ESLAW's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Estrella Immunopharma- Warrants (29/09/2028) with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Estrella Immunopharma- Warrants (29/09/2028)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 251.43%) with ownership activity and broader fundamentals.